ASCO 2026: Phase 3 PEAK study could usher in new second-line therapy for GIST
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) Andrew Wagner (Dana-Farber Cancer…
Browsing: ASCO
ASCO 2026: Personalised vaccine boosts immune activity against brain cancer
At the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) David Reardon, MD, director…
ASCO 2026: GLP-1s may reduce metastatic progression of certain obesity-related cancers
Real-world data shows that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related…
ASCO 2026: Yoga may help cancer survivors sleep better and reduce anxiety, fatigue
For cancer survivors experiencing overall mood disturbance, anxiety, fatigue, or insomnia, regular gentle hatha and…
ASCO 2026: Fasting before and after chemo may help improve treatment response for some people with ovarian cancer
A new study based in Italy found that fasting before and after chemotherapy sessions, when…
ASCO 2026: Less cognitive decline with darolutamide treatment than enzalutamide in people with advanced prostate cancer
Results from the phase 2 ARACOG study, the first direct comparison of the cognitive effects…
ASCO 2026: Trial tests virus-immunotherapy combination for neuroendocrine tumours
A phase I clinical trial is testing whether a tumour-targeting virus can help immunotherapy work…
ASCO 2026: New AI tool may help personalise multiple myeloma treatment
An artificial intelligence-based tool may help physicians determine which newly diagnosed multiple myeloma patients are…
ASCO GU 2026: Enfortumab vedotin pembrolizumab combo may reduce risk of recurrence for some MIBC cases
Results from the phase 3 KEYNOTE-B15 clinical trial found that the combination of the targeted…
ASCO GU 2026: Cancer’s clues in the bloodstream reveal the role androgen receptor alterations play in metastatic prostate cancer
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under…